Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 7/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 6/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.41 |
| ▸ | KMT5A | Q9NQR1 | 2/20 | 0.41 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974946 | 0.72 | DRD2 (0.49) | DRD2ABCG2 | |
| SCHEMBL4741786 | 0.70 | PDPK1 (0.56) | PDPK1KDR | |
| SCHEMBL4894801 | 0.69 | PDPK1 (0.70) | PDPK1 | |
| SCHEMBL4787895 | 0.69 | PDPK1 (0.76) | PDPK1KMT5ASPIN1 | |
| SCHEMBL4745595 | 0.69 | PDPK1 (1.00) | PDPK1 | |
| SCHEMBL4890843 | 0.65 | PDPK1 (1.00) | PDPK1KDRKMT5ASPIN1 | |
| SCHEMBL4899329 | 0.65 | PDPK1 (0.76) | PDPK1 | |
| SCHEMBL4745705 | 0.65 | PDPK1 (0.54) | PDPK1 | |
| SCHEMBL4744364 | 0.65 | PDPK1 (0.54) | PDPK1 | |
| SCHEMBL4888580 | 0.65 | PDPK1 (0.84) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | PDPK1 1/4885DRD2 1112/4885KDR 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.